Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Colorectal Neoplasms 120Carcinoma, Hepatocellular 69Ovarian Neoplasms 64Neoplasms 36Carcinoma, Non-Small-Cell Lung 35Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 23Colonic Neoplasms 21Breast Neoplasms 19Endometrial Neoplasms 18Neoplasm Metastasis 17Uterine Cervical Neoplasms 15Stomach Neoplasms 15Rectal Neoplasms 15Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Recurrence 7Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Bevacizumab × 1 year × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡